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Abstract As with many cancer treatments, tumor treating
fields (TTFields) target rapidly dividing tumor cells. During
mitosis, TTFields-exposed cells exhibit uncontrolled mem-
brane blebbing at the onset of anaphase, resulting in aberrant
mitotic exit. Based on these criteria, at least two protein com-
plexes have been proposed as TTFields’ molecular targets,
includingα/β-tubulin and the septin 2, 6, 7 heterotrimer. After
aberrant mitotic exit, cells exhibited abnormal nuclei and signs
of cellular stress, including decreased cellular proliferation
and p53 dependence, and exhibit the hallmarks of immuno-
genic cell death, suggesting that TTFields treatment may in-
duce an antitumor immune response. Clinical trials lead to
Food and Drug Administration approval for their treatment
of recurrent glioblastoma. Detailed modeling of TTFields
within the brain suggests that the location of the tumor may
affect treatment efficacy. These observations have a profound
impact on the use of TTFields in the clinic, including what
co-therapies may be best applied to boost its efficacy.
Keywords Glioblastoma . Tumor treating fields . Malignant
glioma . Septin . Tubulin . Computer modeling .
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Introduction
Alternating electric fields therapy is a novel anticancer treat-
ment that disrupts tumor cell mitosis. The first US Food and
Drug Administration (FDA)-approved indication is for the
treatment of recurrent glioblastoma. In this review, we will
discuss the basic cell biology effects, physics properties, and
clinical trial data of this emerging anticancer treatment.
Cell Biology Effects of Tumor Treating Fields
on Mitotic Tumor Cells
Electric fields have long been known to interact with biolog-
ical material and this has been exploited for medical treatment
by effecting the depolarization of electrically excitable nerves
and muscles, or inducing the deep heating of tissues. Dr.
Yorum Palti at the Rappaport Institute in Israel developed a
technology to deliver electric fields that affect dividing cell
viability. Analysis of this effect on cell viability revealed a
tight peak of cytotoxic effect in all cell types tested between
150 and 200 kHz , wh i ch was no t appa r en t a t
frequencies <50 kHz and>500 kHz. This cytotoxicity also
increased with field intensity. Based on their ability to kill
tumor cells in culture, these alternating electric fields have
been referred to as tumor treating fields (TTFields) [1••, 2••].
During mitosis, exposure of cells to these fields results in
violent membrane blebbing and cells exhibited disruption of
microtubule spindle elements and chromosomal order
post-mitosis [2••, 3••]. An enigmatic feature of the effect that
TTFields have on cells is that the incident angle to the mitotic
plate dictates the magnitude of cellular damage. When
TTFields were perpendicular to the plane of division, cells
were relatively unaffected but when the TTFields were paral-
lel to the plane of division, cells exhibited a higher degree of
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mitotic failure [2••]. TTFields exposure perturbs both micro-
tubule spindle elements and mitotic chromosomal order, dem-
onstrating that cells are physically deranged post-mitosis. This
suggests that TTFields interact with elements, likely a protein
structure, within the cell that possesses a fixed structural rela-
tionship to the plane of division.
Detailed analysis has demonstrated that TTFields-induced
mitotic disruption specifically occurs coincident with the exit
frommetaphase [3••]. Early reports showed that cells exposed
to TTFields exhibited increase time in mitosis [2••]. Com-
pared with paclitaxel treatment, which blocks metaphase exit,
there was no gross perturbation in progression through mitosis
[3••]. Microtubule structure during metaphase and both cyclin
B and securin destruction was normal [4]. Time-lapse micros-
copy of mitotic cells stained with a vital DNA dye for staging
of mitosis revealed that TTFields-induced membrane bleb-
bing occurs at the expected time of metaphase exit [3••]. Since
this is triggered by the capture of metaphase spindle microtu-
bules by the kinetochores of chromosomes subsequent to
metaphase plate formation (see below), this suggests that in
the presence of TTFields metaphase spindle formation and
function are normal. However, a measurable increase in the
4N DNA content of TTFields-treated cells combined with a
persistence in phosphorylated histone H3 levels in synchro-
nized cultures treated with TTFields indicated aberrant mitotic
exit [3••, 4]. Together, these data demonstrate that
TTFields-treated cells transit normally through metaphase
but become deranged during anaphase due to the violent dis-
ruption of mitotic order secondary to membrane blebbing
followed by aberrant mitotic exit.
TTFields have also been shown to cause tumor regression
in animal models and human cancers. Treating mice with a
number of injected tumor models, including CT26 colon ad-
enocarcinoma, B16/F1 melanoma, Lewis lung carcinoma, and
the highly invasive VX2 carcinoma in rabbits, all demonstrat-
ed TTFields-induced tumor regression [1••, 5, 6]. Interesting-
ly, treatment of VX2 tumors implanted under the kidney cap-
sule following tumor establishment led to a marked decrease
in lung metastasis when analyzed 35 days after implantation.
This was accompanied by a statistically significant increase in
the number of immune infiltrates within successful lung me-
tastases in treated animals. Together, these studies demonstrat-
ed that TTFields could penetrate the body and affect cellular
physiology and lead to their testing against human gliomas
and a successful phase III clinical trial (see below). Chen
et al. [7] have also applied similar intermediate frequency
alternating electric fields to B16/F10 melanoma cells, show-
ing similar effects both in vitro and ex vivo. Interestingly, they
also provide evidence that CD34-positive cell numbers were
reduced, indicating an effect on the tumor microvasculature in
the treated tumors [7]. Beyond being necessary for perfusion
of oxygen and nutrients into the tumor bed, tumor endotheli-
um has been implicated in supporting the intratumoral
immune inhibitory environment [8, 9]. These data suggest that
beyond their effects on the malignant cells, TTFields may
contribute to tumor regression by both starving the tumor
and reducing intratumoral immune privilege.
Basis of Vulnerability to TTFields During Mitosis
The cell cycle is a regimented process that controls cellular
growth and proliferation. Since TTFields affect cells during
mitosis, this suggests a specific vulnerability within mitosis to
TTFields-induced perturbation. Cellular growth and biomass
accumulation occurs during interphase, which is subdivided
into the G1, S, and G2 phases. Non-dividing and post-mitotic
cells exist in a state referred to as G0. Cell division and daughter
cell production occurs during mitosis, which is further
subdivided into prometaphase, metaphase, anaphase, and telo-
phase. In contrast to mitosis, the lengthy period of interphase is
dominated by metabolic processes; by contrast, mitosis is char-
acterized by processes that are dependent upon the rapid and
precise assembling and functions of complex mitosis-specific
structures. These structures are responsible for three indepen-
dent, albeit coordinated, mechanical functions that are critical
for proper cell division within a limited period of time, roughly
90minutes in typical cultured cells. Therefore, while interphase
is a highly anisotropic stage, the processes that mitosis depends
on possess properties that make them inherently more suscep-
tible to perturbation by electromotive forces introduced into the
cell by TTFields (see below). In addition, as mitosis proceeds,
both the level of order and the demand for spatial and temporal
precision of execution by these structures crescendos from as-
sembly of themitotic spindles to the triggering of the significant
biomechanical forces generated by the cytokinetic cleavage
furrow (CCF) that is capable of dividing the parental cell into
two daughters in only minutes. Therefore, as mitosis proceeds,
cells are likely to be increasingly sensitive to the effects of
alternating electric fields.
Sister chromatids that are condensed during prometaphase
attach to the newly assembled metaphase spindles and migrate
to the cell equator through the action of kinesin motor proteins
to form the metaphase plate [10]. The kinetochores within the
centromeric regions of each sister chromatid capture microtu-
bule ends of the mitotic spindle. Since the kinetochores of
each chromatid pair lays across the chromosomes from each
other, microtubule capture insures that all chromatid pairs are
aligned on the metaphase plate with their constituent kineto-
chores pairs aligned towards the respective pole of the each
forming daughter cells. This also creates physical tension be-
tween the kinetochores, which acts to terminate a signal that
prevents the activation of anaphase-promoting complex C
(APC/C) and metaphase exit [11]. Final kinetochore capture
triggers mitotic exit by permitting the rapid and irreversible
activation of the APC/C ubiquitin ligase activity responsible
8 Page 2 of 10 Curr Neurol Neurosci Rep (2016) 16: 8
for targeting specific proteins for destruction by the S26
proteosome. Destruction of APC/C ubiquinated substrates is
necessary for metaphase exit, including G2 cyclin, cyclin B,
and securin. Cyclin B is the allosteric activator of the
cyclin-dependent kinase 1, whose activity both initiates mitosis
and drives cells into metaphase while simultaneously inhibiting
processes necessary for anaphase. Securin inhibits the protease
separase that cleaves the cohesin protein complexes, which
help to entangle sister chromatids prior to anaphase [12]. Since
APC/C is only activated following the capture of the last kinet-
ochore, the entry into anaphase therefore requires proper mi-
crotubule spindle formation and function [13].
Within anaphase, two structures form, perform their func-
tion, and are then rapidly disassembled. The microtubular
anaphase spindle performs two functions within minutes of
anaphase entry. During this time, it is assembled between the
separating daughter chromosomes, rapidly grow from the
midline, and push them into the forming daughter cells. The
midline of the anaphase spindle is essential for the organiza-
tion and regulation of the CCF (Fig. 1). The combination of
the precise coordination of events during anaphase and the
short time frame in which they need to be executed likely
makes them sensitive to the disruptive impacts of the
TTFields. To accomplish this, the anaphase spindle midline
contains a number of regulatory proteins, including the
centralspindlin complex, RhoGEF, and ECT2, which recruits
the adaptor protein anillin, which, in turn, binds to the septin 2,
6, 7 complex [14]. ECT2 is subsequently delivered from the
midline to the CCF where it is instrumental in dictating its
localization and regulating its contraction during cytokinesis
[15]. Upon its recruitment to the CCF, the septin heterotrimers
oligomerizes into a highly ordered cytoskeleton-like scaffold
that functions to recruit and organize the actionmyosin con-
tractile elements required for furrow ingression and the sepa-
ration of the daughter cells [14, 16–20]. In addition to its
function within the CCF, septins also cross-link F-actin bun-
dles within the submembranous actin cytoskeleton [21, 22•,
23, 24]. This structure must possess adequate rigidity to with-
stand the hydrostatic pressures within the cytoplasm generated
by ingression of the cytokinetic furrow. Failure to restrain
these forces leads to rupture of the connection between this
structure and the overlying plasma membrane, leading to
membrane blebbing [21].
Molecular Targets of TTFields
The disruption of cells by TTFields during mitosis suggests
that they exert forces or movement on definable molecular
targets, the functions of which are critical to a mitotic process
or processes. Proteins possess complex charge structures on
their surfaces that are dependent on the charges of surface
amino acid side chains. The arrangement of acidic and basic
side chains can result in regional separations of surface charge
imparting a dipole moment onto the protein, similar to that
observed in bar magnets. The dipole moments of such pro-
teins will align within an electric field to orient towards the
oppositely charged pole of the fields. Therefore, the
re-polarization of the alternating field will induce a
re-alignment of the protein dipoles within the field. Thus, such
proteins would be expected to experience rotational forces
within TTFields [2••].
Fig. 1 Tumor treating fields
(TTFields) interact with cells
during mitosis. The cell cycle can
be separated into interphase and
mitosis. Interphase is divided into
G1, S, and G2, during which cells
grow larger by accumulation of
biomass through metabolic pro-
cesses. Mitosis is divided into
prometaphase, metaphase, ana-
phase, and telophase. These dif-
ferent phases are defined and
dominated by biomechanical pro-
cesses that have evolved to ensure
the faithful inheritance of the pa-
rental genome in each newly
formed daughter cell. TTFields
affect cells within anaphase.
APC/C = anaphase-promoting
complex C
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Proteins that are important to mitotic progression that have
high dipole moments have been suggested to be targets of
TTFields perturbation, include the α/β-tubulin monomeric
subunit of microtubule and the mitotic septin complex. α/
β-Tubulin form the building blocks for microtubules. Taxanes
are commonly used chemotherapeutic agents that bind and
stabilize microtubules and can cause mitotic catastrophe by
trapping cells within metaphase [25]. The functional subunit
of microtubules is a heterodimer consisting of α- and β-tubu-
lin, which possesses a high predicted dipole moment of 1660
Debyes (D) (PDB 1JFF) [26, 27]. Therefore, it is possible that
TTFields interfere with a critical mitotic function performed
by microtubules [1••, 2••], including the formation of the
metaphase and anaphase spindles and their respective me-
chanical functions [28, 29], or the astral microtubules that help
regulate the CCF [30].
The septin 2, 6, 7 heterotrimer also possesses a high pre-
dicted dipole moment of 2711 D (PDB 2QAG), [27, 31]. As
described above, the septin 2, 6, 7 heterotrimeric complex is
required for functions that are necessary for the later stages of
cell division. The complex rapidly polymerizes and structur-
ally helps to organize the CCF during anaphase. Once recruit-
ed, it then oligomerizes and organizes the CCF above the
equatorial cleavage plane by binding to F-actin filaments
and spatially regulates myosin activation. The perturbation
of the septin complex is particularly enticing because of its
known roles in the regulation of CCF function and actin bun-
dle cross-linking and organization of structures such as the
cellular submembranous actin cytoskeleton that is required
for its rigidity [21, 22•]. Short hairpin RNA-driven depletion
of septin 7 resulted in mitotic blebbing with similarities to that
seen with TTFields treatment [2••, 3••, 22•], and an increase in
cell size [22•, 32]. Septins also interact with microtubules and
several microtubule interacting proteins that influence their
position and stability during both interphase and mitotsis
[33]. Therefore, perturbation of either α/β-tubulin or septins
may perturb microtubule function. Unlike errors or damage
that initiate the G1/S, G2/M or spindle assembly check point
(SAC), catastrophic errors occurring after the cell anaphase
commitment are unlikely to be corrected [34]. These observa-
tions strongly suggests a mechanism of action where TTFields
perturb mitosis by interfering with normal septin localization
and function during mitosis, leading membrane blebbing and
aberrant mitotic exit.
Mitotic Effects of TTFields Result in Postmitotic
Stress
This aberrant mitotic exit results in a high degree of cellular
stress, as indicated by increased cytoplasmic vacuoles, as well
as decrease in proliferation and apoptosis [3••]. Cells
experiencing mitotic exit in the absence of division have been
shown to experience p53-dependent G0/1 cell cycle arrest and
apoptosis [35, 36]. Likewise, cells exposed to TTFields subse-
quently exhibit decreased proliferation with a failure to enter S
phase and increased levels of apoptosis beginning>24 hours
after TTFields exposure in a p53-dependent manner. Apoptosis
occurs after 24 hours of TTFields exposure during mitosis in a
p53-dependent manner [3••]. These data strongly suggest that
the efficacy of treatment may be influenced by tumor genetics.
There are different ways in which TTFields may affect
patient outcomes. TTFields are able to disrupt cells during
mitosis and this leads to aberrant mitotic exit and cell death.
As in the case of spindle poisons, which trigger the SAC, cells
affected by TTFields exhibit different fates, including death in
anaphase or aberrant exit from mitosis similar to mitotic slip-
page. In this way, the mechanism of action may be similar to
that proposed for other cancer therapies that destroy tumor
cells based on their increased proliferation rate making them
more susceptible to agents that target dividing cells, such as
spindle poisons. Alternatively, there are multiple lines of evi-
dence suggesting that TTFields induce an immunological re-
sponse against tumors.
Several lines of evidence support a possible immune depen-
dency for TTFields efficacy. Senovilla et al. showed that tetra-
ploid cells that are produced under experimental conditions that
perturb mitotic exit exhibit the hallmarks of immunogenic cell
death (ICD) [37]. This programmed form of cell death evokes
an immune response against the dying cells through cell surface
expression of the endoplasmic reticulum chaperone protein,
calreticulin, and the secretion of the cytokine/alarmin, high mo-
bility group box 1 protein (HMGB1), and adenosine triphos-
phate [38••, 39]. When injected into mice, these dying cells
produced a protective immunization against subsequent chal-
lenge with the same tumor cells [37]. Additionally, it has been
demonstrated that cells made tetraploid by pharmacologic ma-
nipulation also express natural killer group 2, member D
(NKG2D) and DNAX accessory molecule 1 (DNAM) ligands
on their surfaces, which provoke natural killer cell clearance of
the expressing cells [40]. Cells that are exposed to TTFields
exhibit cellular responses that are consistent with ICD, includ-
ing the cell surface expression of calreticulin and depletion of
HMGB1. Kirson et al. [5] showed that a brief TTFields treat-
ment of subrenal capsule-injected VX2 tumor in rabbits mark-
edly reduced subsequent metastatic spread to the lungs. Exam-
ination of metastatic tumors in the lungs of these
TTFields-treated rabbits showed a significant increase in im-
mune infiltrates, likely indicating a requirement for increased
immune protective stroma for tumors capable of developing in
these animals [5]. In the pivotal EF-11 trial that lead to FDA
approval for the treatment of recurrent glioblastoma, response
typically occurred 6.6–9.9 months following the onset of treat-
ment, at which point responders exhibited rapid tumor regres-
sion [41•]. This pattern of delayed response is also consistent
with an immune mechanism of tumor rejection. Finally, clinical
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data strongly suggest that concurrent use of dexamethasone, a
potent immunosuppressive agent, is correlated with poor out-
come (see below) [41•, 42••].
TTFields Therapy for Recurrent Glioblastoma
The current FDA-approved indication for the TTFields therapy
device is treatment of recurrent glioblastoma. The
first-in-human pilot trial for the safety and efficacy of TTFields
therapywas conducted in 2004 to 2007 and enrolled 10 patients
with recurrent glioblastoma [1••]. The most common adverse
event was contact dermatitis, which occurred in nine patients as
a result of hydrogel-induced irritation of the scalp. Two patients
experienced partial seizures that were related to their tumors.
No toxicity on blood count or chemistry was seen, except for
elevated liver enzymes in those taking anticonvulsants. The
median overall survival (mOS) of the 10 patients was
14.4 months. The time to tumor progression was 6.0 months
and the 1-year survival rate was 67.5 % [1••]. There was one
complete and one partial responder who were alive at 84 and
87 months, respectively, from treatment initiation [43]. Further-
more, the intensity of electric fields as directly measured in one
patient was validated to be within 10 % of the values estimated
by computer modeling [1••].
The phase III registration trial was conducted in 2006 to 2009
and the primary end point was overall survival [44••]. In the
intent-to-treat population, the mOSwas 6.6 months for TTFields
versus 6.0 months for best physician’s choice (BPC) chemother-
apy, with a hazard ratio (HR) of 0.86 (p=0.27). About 31 % of
the BPC cohort received bevacizumab alone or in combination
with chemotherapy. The median progression-free survival (PFS)
of TTFields and BPC chemotherapy was 2.2 and 2.1 months,
respectively (HR 0.81; p=0.16), and the PFS at 6 months was
21.4 % and 15.1 %, respectively (p=0.13). One-year survival
rate was 20 % in both cohorts. The outcome of the trial indicates
that TTFields probably has equivalent efficacy when compared
with chemotherapy and bevacizumab.
Grade 1 or 2 scalp irritation were the most common
adverse events associated with the device. Shifting of the
arrays slightly during array exchange and by applying top-
ical corticosteroid can minimize this irritation [45]. There
was far less hematological toxicity, appetite loss, constipa-
tion, diarrhea, fatigue, nausea, vomiting, and pain associ-
ated with the device when compared to BPC chemothera-
py. Furthermore, analysis showed that device-treated pa-
tients had better cognitive and emotional functions. Based
Fig. 2 Transducer array
placement on the scalp. As
generated by the mapping
software NovoTAL, two pairs of
arrays are positioned orthogonally
in an anterior–posterior (A, B), as
well as right–left (C, D),
arrangement. These two pairs of
arrays are connected to an electric
field generator, which is, in turn,
either connected to a portable
battery pack or a power cord that
can be inserted directly into an
electric outlet (not shown)
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on the equivalent efficacy results and absence of serious
associated toxicities, the FDA approved on 8 April 2011
the TTFields therapy for the treatment of recurrent
glioblastoma.
The apparent discrepancy in the overall survival rates be-
tween the pilot study and the registration trial prompted a
series of post hoc analyses of the trial data. First, one of the
analyses centered on responders and it showed that five of 14
responders treated with TTFields monotherapy had prior
low-grade histology, while none of the seven responders treat-
ed with BPC chemotherapy did [41•]. Second, the analysis
revealed significantly less dexamethasone use in responders
versus nonresponders [41•]. Responders in the TTFields
monotherapy group received a median dexamethasone dose
of 1.0 mg/day while nonresponders received 5.2 mg/day. A
similar difference was also noted in the median cumulative
dexamethasone dose of 7.1 mg for responders versus
261.7 mg for nonresponders. In the chemotherapy cohort, the
median dexamethasone dose was 1.2 mg/day for responders
versus 6.0 mg/day for nonresponders. However, the median
cumulative dexamethasone dose was not significantly different
(348.5 mg for responders vs 242.3 mg for nonresponder).
These data suggest that TTFields efficacy may be influenced
by concurrent dexamethasone use, which is a clinically modi-
fiable factor. This finding prompted an in-depth analysis of the
dexamethasone effect in the entire trial population.
Applying an unsupervised modified binary search algo-
rithm that stratified the TTFields monotherapy arm of the
phase III trial based on the dexamethasone dosage that pro-
vided the greatest statistical difference in survival revealed
that subjects who used>4.1 mg/day dexamethasone had a
markedly shortened mOS of 4.8 months compared with those
who received≤4.1 mg/day (mOS of 11.0 months) [42••]. Pa-
tients in the chemotherapy arm were observed to have a sim-
ilar but less robust dichotomization; those who used > 4.1
and ≤ 4.1 mg/day dexamethasone had a mOS of 6.0 and
8.9 months, respectively. This difference in overall survival
based on dexamethasone dose was unrelated to tumor size but
most likely from interference with patient immune effector
function. A single institution validation cohort of patients
treated with TTFields therapy, using their CD3+, CD4+, and
CD8+ T lymphocytes as a marker of immune competency,
suggested the importance of immune competence to TTFields
therapy. Importantly, a dexamethasone dosage of > 4.0 mg/
day was also found to be a poor prognostic factor in newly
diagnosed patients who completed radiotherapy [46],
supporting the conclusion that dexamethasone can interfere
with treatment. With successive increases in dexamethasone
dosage, both cohorts reached an inflection point near 8.0 mg/
day, after which the rate of survival decreased slowly thereaf-
ter. Taken together, dexamethasone exerts a generalized and
profound interference on the efficacy of both TTFields and
chemotherapeutic treatment against glioblastoma. Therefore,
dexamethasone use should be minimized [47].
Transcanial Distribution of Electric Fields
from Transducer Arrays
A number of factors, including a medium’s electric conductiv-
ity and relative permittivity, can affect electric field
distrubution. Since each tissue composition is unique, the in-
tracranial structures must therefore be characterized based on
their conductivity and permittivity values. The highly hetero-
geneous architecture of the brain therefore distort electric fields
induced by an external source. Electric fields are generally
defined as instantaneous changes in electric potential. This
change in electric potential results in electromotive disruption
of mitotic structures and is therefore the basis for the therapeu-
tic benefit of TTFields [3••]. TTFields therapy for glioblastoma
is delivered by two pairs of transducer arrays positioned or-
thogonally on the shaved scalp, adhered by a thin layer of
conductive gel that provides good conductivity (Fig. 2) [48] .
TTFields are generated by a battery-powered alternating cur-
rent generator, operating at 200 kHz, with maximum voltage
alternating from +50 to –50 V. To obtain a comprehensive
model of the electric fields distribution in the brain, computer
modeling can be performed using co-registered patient Digital
Imaging and Communications in Medicine (DICOM) datasets
f r om T 1 -w e i g h e d p o s t g a d o l i n i um , T 2 , a n d
magnetization-prepared rapid gradient-echo magnetic reso-
nance images. Previously, Lok et al. [49•] have shown a het-
erogeneous distribution of electric fields in the brain, and the
regions adjacent to the ventricular horns had a particularly high
electric field intensity (Fig. 3). This is likely due to the higher
electric conductivity of cerebrospinal fluid (CSF) than the sur-
rounding tissues, which behaves like the terminal of a capaci-
tor, with the surrounding tissues functioning much like a di-
electric between conductive terminals. Since a dielectric medi-
um generally retains charge, the rate at which the medium is
able to collect and retain the charge is defined by its conduc-
tivity and relative permittivity. At 200 kHz, the effect of per-
mittivity is overwhelmed by the conductivity of the medium
[50]. Furthermore, the rate at which the medium is able to
collect and retain charges is frequency dependent. At high
Fig. 3 Computer modeling of electric field distribution within the brain.
T1-weighed postgadolinium, T2, and magnetization-prepared rapid
gradient-echomagnetic resonance images are imported into Simpleware’s
ScanIP 7.0 Suite to perform segmentation of various brain structures,
including the scalp, skull, dura, cerebrospinal fluid, gray matter, white
matter, brainstem, cerebellum, bilateral ventricles, gross tumor volume,
and tumor necrotic core. (A) An air-tight volumetric mesh is then gener-
ated for finite element analysis using COMSOL Multiphysics. (B) The
distribution of electric fields within the brain is inhomogeneous, with the
highest fields at the frontal and occipital horns of the lateral ventricles, as
well as the medial surface of the glioblastoma
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frequencies, each medium has a unique capacitive reactance
characteristic of the medium’s conductivity, and thus the me-
dium only has limited time to collect a finite amount of charge
and retain it before the field collapses as the polarity changes
direction, thereby discharging the initially retained charge be-
fore repeating the process. Since CSF has a low permittivity
value compared with its surrounding tissues, it is a poor dielec-
tric medium and thus charges will migrate through the fluid
layer at a much faster rate with minimal charge retention. This
explains why most of the CSF exhibits very low electric field
intensity. However, this is not true at the interface betweenCSF
and its adjacent brain tissue. The computed electric field dis-
tribution revealed that the ventricular horns exhibit a higher
electric field intensity than the rest of the CSF space. This is
likely due to the geometry of the region coupled with increased
electric potential and reactance causing large field changes.
The electric properties of gliomas are likely to vary among
patients, depending on their tumor composition. Tumors with
larger necrotic cores are likely to exhibit higher field intensi-
ties in the gross tumor volume owing to the capacitive reac-
tance as explained above. In contrast, tumors with smaller or
no necrotic core will likely exhibit lower field intensities at the
center of the volume due to absence of a conductive medium
to act as an electric current source. This may become clinically
relevant owing to the increased requirement for time of expo-
sure to TTFields as the outer layers of the gross tumor volume
is treated slowly because of lower field intensities.
The Use of TTFields Therapy in Clinical Practice
The post-FDA-approved use of TTFields therapy in routine
clinical practice may differ from that in the registration trial
because of the stringent entry criteria built into the trial. There-
fore, a Patient Registry Dataset (PRiDe) was developed in an
effort to capture pertinent clinical practice data. This dataset
consisted of 457 patients from 91 treatment centers in the US.
Patients treated and captured in PRiDe had a mOS of
9.6 months compared with the 6.6 months in the TTFields
monotherapy arm in the registration trial [44••, 51]. The
1-year OS rate was also longer at 44 % compared with
20 %, respectively [44••, 51]. The difference in survival char-
acteristics is most likely due to the higher proportion of pa-
tients treated with TTFields at first recurrence in PRiDe
(33 %) than that in the registration trial (9 %). Treatment at
an earlier time point in the process of disease progression may
provide a higher efficacy than treatment at a later time point.
Absence of prior bevacizumab usage was also favorable [51].
However, the heterogeneity in the adjunctive treatments used
in conjunction with TTFields therapy in the PRiDe dataset,
which included cytotoxic chemotherapy, bevacizumab, or
even alternative medicine that were not adequately captured,
is an important caveat that makes it statist ically
noncomparative with the TTFields monotherapy arm in the
registration trial.
Efficacy of TTFields Therapy for Newly Diagnosed
Glioblastoma
TTFields therapy is currently being tested in glioblastoma pa-
tients after their initial radiotherapy and concomitant daily temo-
zolomide. In this phase III trial, 700 patients were randomized
2:1 to received either TTFields plus adjuvant temozolomide or
temozolomide alone, respectively [52, 53]. The primary end
point was PFS. In a prespecified interim analysis of the first
315 patients after a minimum follow-up of 18 months, the
intent-to-treat cohort that received TTFields plus temozolomide
had a longer PFS than the cohort treated with temozolomide
alone (median 7.1 vs 4.0 months, HR 0.6; log-rank p=0.0014).
The mOS also favors the TTFields plus temozolomide group
(19.6 vs 16.6 months, HR 0.75; log-rank p=0.034), as well as
the per-protocol population that started the second cycle of treat-
ment (20.5 vs 15.5 months, HR 0.67; log-rank p=0.0072).
The trial population had no unexpected adverse events.
Grade 3 and 4 hematological toxicities between the TTFields
plus temozolomide and temozolomide alone cohorts (12 % vs
9 %), gastrointestinal disorders (5 % vs 2 %), and convulsions
(7 % vs 7 %) were not significantly different. Only scalp
reaction was more common than those that had temozolomide
only.
Conclusion and Future Directions
TTFields interferes with α-/β-tubulin and septin 2, 6, 7
heterotrimer function in tumor cells during mitosis. A phase
III clinical trial has shown a favorable toxicity profile in re-
current glioblastoma and promising efficacy data in newly
diagnosed glioblastoma. Computer modeling showed inho-
mogeneous distribution of electric fields within the brain. Fu-
ture investigations will likely include combination treatments,
including immune therapies, that can potentially boost the
existing efficacy of TTFields monotherapy.
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